Caris Life Sciences, Inc.
CAINASDAQHealthcare● Active
$16.74
+$0.25(+1.54%)
Market Cap$4.7B
P/E Ratio—
52W High$42.5
52W Low$14.19
Caris Life Sciences, Inc. (CAI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CAI · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.81B | $0.41B | $0.31B | $0.26B | $0.29B |
| Cost of Revenue | $0.27B | $0.23B | $0.22B | $0.18B | $0.11B |
| Gross Profit | $0.54B | $0.18B | $0.09B | $0.08B | $0.18B |
| Gross Margin %(computed) | 66.40% | 43.37% | 29.17% | 30.96% | 62.64% |
| Operating Expenses | |||||
| R&D Expenses | $0.05B | $0.11B | $0.12B | $0.10B | $0.00B |
| G&A Expenses | $0.22B | $0.17B | $0.15B | $0.16B | $0.03B |
| Total Operating Expenses | $0.49B | $0.44B | $0.41B | $0.40B | $0.05B |
| Operating Income | $0.05B | ($0.26B) | ($0.32B) | ($0.32B) | $0.14B |
| Operating Margin %(computed) | 5.56% | -62.37% | -104.38% | -122.16% | 47.31% |
| Interest Income | $0.02B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.06B | $0.05B | $0.03B | $0.03B | $0.06B |
| Income Before Tax | ($0.07B) | ($0.28B) | ($0.34B) | ($0.32B) | $0.03B |
| Income Tax Expense | $0.47B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.54B) | ($0.28B) | ($0.34B) | ($0.32B) | $0.03B |
| Net Margin %(computed) | -66.25% | -68.38% | -111.53% | -124.12% | 9.43% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.90 | $-2.70 | $-1.82 | $-1.57 | $1.55 |
| Wtd Avg Shares | 1.67B | 0.25B | 0.25B | 0.25B | 0.02B |
| EBITDA | $0.01B | ($0.18B) | ($0.26B) | ($0.25B) | $0.25B |
| EBITDA Margin %(computed) | 1.40% | -44.38% | -85.19% | -95.13% | 86.55% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Caris Life Sciences, Inc. data
About Caris Life Sciences, Inc. (CAI) Income Statement
Caris Life Sciences, Inc. (CAI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CAI reported revenue of $0.81B, gross profit of $0.54B (gross margin 66.40%), and net income of ($0.54B) — a net profit margin of -66.25%.
Frequently asked questions
CAI · 4 questionsCaris Life Sciences, Inc. (CAI) reported revenue of $0.81B for 2025, up 97.0% year-over-year.
CAI revenueCAI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08